Articles tagged with Breast Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A team of researchers at Queen Mary University of London discovered that disrupting a single amino acid in the vimentin protein makes breast cancer cells behave like stem cells. This mutation promotes tumour growth and increases cancer stemness in an oestrogen-independent manner.
A preclinical study reveals that tumors drive clot formation by releasing chemokines, prompting immune cells to release small vesicles that attach to cell fragments, forming life-threatening clots. The findings may lead to diagnostic tests and safer therapies to target the root of blood clotting risk.
New cyanine-carborane salts show promise in eradicating metastatic breast cancer tumors with minimal side effects. The therapy targets specific proteins in cancer cells, allowing for precise killing of diseased cells while sparing healthy tissue.
Researchers at University of Melbourne and Pfizer discover new insights into a dual-target drug that may supercharge cancer-fighting immune cells, potentially leading to improved outcomes for breast cancer patients. The study found that this approach can enhance anti-tumor immunity by intratumoral CD8+ T cells.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Researchers at Stanford Medicine classified breast cancers into three main groups based on structural variations in their DNA, including repeats of oncogenes and small DNA circles. Understanding these variations could aid physicians in making decisions and point to new targeted therapeutic interventions.
A new study reveals that breast cancer survivors face significant psychosocial challenges due to fear of recurrence, affecting various aspects of their lives. The study found that nearly all affected domains were impacted by the fear, with those having greater fear experiencing more frequent disruptions.
In Japan, breast cancer screening participation rates dropped significantly during the pandemic, affecting specific subgroups such as those aged 45-49 and living in towns/villages. The overall rate declined from 48.3% to 47.1%, with municipalities seeing a decrease but worksites an increase.
The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.
A new tool named retriever extracts disease-specific drug response signatures to predict cancer treatment combinations, improving personalized treatment strategies. The tool refines predictions using single-cell RNA sequencing data and demonstrates its potential in identifying effective treatments for triple-negative breast cancer.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
A new study published in The Lancet Digital Health found that AI-supported breast cancer screening increased the detection of early-stage invasive cancers by 24% compared to traditional screening. AI also identified pre-cancerous lesions with a 51% higher rate, without increasing false positives.
A study from the University of Surrey reveals that delays in cancer diagnosis for pregnant women are often due to misattributed symptoms as normal pregnancy changes. Women experiencing more specific symptoms, such as breast lumps, are more likely to receive quicker diagnoses and referrals.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
A new study published in Nature Medicine shows a promising approach to preventing metastases in breast cancer patients. Researchers found that administering digoxin reduced circulating tumour cell clusters by an average of 2.2 cells, significantly decreasing the risk of metastasis.
A cognitive science professor at UC Merced proposes a suite of video games to accelerate cancer research using artificial intelligence and gamified citizen science. The 'Cancer Wars' initiative aims to harness the collective problem-solving power of millions of gamers to tackle complex scientific problems.
A new combination therapy combining systemic interferon-I with local imiquimod application showed promising results in treating melanoma and breast cancer. The therapy activated the adaptive immune system to fight distant metastases, reducing tumor relapses and increasing sensitivity to checkpoint inhibitors.
A new approach to cancer therapy is being developed by inhibiting mechanotransduction, a process that regulates processes such as tumour progression and wound healing. The INTROPY project aims to validate the potential of six molecules in blocking this process, offering a new strategy for cancer treatment.
The RSClin Tool N+ provides more accurate estimates of recurrence risk and individual chemotherapy benefit in node-positive breast cancer. The tool combines clinical and pathologic factors with the 21-gene Oncotype DX Breast Recurrence Score to predict patient-level prognosis and treatment benefit.
Researchers have developed a novel small molecule that completely eliminates breast cancer tumors and shrinks large tumors in mice with a single dose, with minimal side effects. This compound shows promise as a transformative treatment option for estrogen receptor-positive (ER+) breast cancer.
Researchers explore HER2-low breast cancer, a new clinical subtype that benefits from novel treatments and personalized care. Current testing methods are not always accurate, calling for better detection methods to correctly identify patients who can benefit from these new therapies.
A study demonstrates the effectiveness of telephone-delivered acceptance and commitment therapy in reducing fatigue's interference with functioning and improving quality of life for metastatic breast cancer survivors. The remote intervention showed promise in reducing sleep interference, leading to improved sleep quality and a greater ...
A study found that a simple blood test could predict breast cancer risk in older women by measuring biological aging via DNA methylation changes. Lifestyle factors, such as obesity and hormone replacement therapy, also influenced epigenetic aging and breast cancer risk.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.
The FDA has revoked authorization for the use of Red Dye 3 in food and ingested drugs, citing studies linking it to cancer in laboratory male rats. This decision is an important step forward in addressing modifiable risk factors that have the potential to reduce cancer risk.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has successfully enrolled over 108,000 women worldwide for a randomized controlled trial comparing 2D and 3D mammography. The study aims to determine whether 3D mammography is more effective in reducing advanced breast cancer risk.
Researchers at Case Western Reserve University have made a groundbreaking discovery about the molecular switches within the estrogen receptor protein that contribute to breast cancer. The study's findings offer new tools and ideas for developing more effective treatments for this devastating disease.
A study found that RAD51 testing can predict which patients with early-stage HER2-negative breast cancer may respond to neoadjuvant therapy. Patients with high RAD51 protein levels showed a higher response rate to PARP inhibitor treatment, suggesting the potential for personalized treatment strategies.
A nationwide cohort study in Korea found that postdiagnosis weight gain is associated with an increased risk of heart failure after breast cancer development. Effective weight intervention can protect cardiovascular health, particularly within the first few years after diagnosis.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
A multi-institutional study led by Mayo Clinic researchers has improved the accuracy of genetic testing for BRCA2 variants, enabling precise risk assessments and personalized treatment plans. The findings will aid in identifying patients who may benefit from targeted therapies such as PARP inhibitors.
A recent study published in Nature Medicine found that AI significantly improves breast cancer detection rates, detecting an additional cancer case per 1,000 women screened. The results show improved efficiency without increasing false positives or unnecessary follow-ups.
Early detection of breast cancer can lead to less intensive treatments, saving the Canadian healthcare system $459.6M over women's lifetimes and 3,499 breast cancer deaths. Screening mammograms and diagnostics costs are easily offset by earlier stage treatment.
A University of Cincinnati Cancer Center study identifies microRNA miR-205 as a promising new target to overcome breast cancer treatment resistance and improve outcomes. The research found that boosting levels of miR-205 could block the production of MED1, a protein responsible for treatment resistance, and improve treatment outcomes.
The alliance aims to generate evidence supporting national guideline inclusion and healthcare provider adoption of Myriad's Precise MRD test. The studies will explore the test's utility in breast, gastrointestinal, genitourinary and gynecological cancers.
Weill Cornell Medicine has received a $2.3 million CDC grant to enhance care coordination for young breast cancer survivors, focusing on racially and socio-economically diverse groups to reduce symptom burden and improve survival outcomes.
Scientists cultivate stable tumor organoids directly from blood samples of breast cancer patients, revealing a molecular signaling pathway that ensures cancer cell survival and resistance to therapy. The team develops an approach to specifically eliminate these tumor cells in lab experiments.
A case-control study found a link between advanced breast cancer stage and prevalent cardiovascular disease, with hormone receptor-positive and ERBB2-negative disease being more affected. Future studies are needed to confirm these findings and investigate interventions to improve patient outcomes.
Research from the University of Texas M. D. Anderson Cancer Center suggests that individuals with pre-existing cardiovascular disease are more likely to have advanced or metastatic breast cancer. The study found a 10% increased risk of CVD in patients with late-stage breast cancer compared to those with early-stage cancer.
Genetic testing for cancer risk should always include healthcare providers and genetic counseling to ensure users fully understand their results and receive proper guidance. The authors call on the FDA to provide clear rules for using these tests, particularly for minors.
A cohort study found a decrease in localized invasive breast cancer and regional invasive breast cancer since the 2009 guideline changes, but no decrease in advanced cancer stages. Further research is needed to understand these trends.
Researchers discovered that aggressive breast cancer prompts nearby immune cells to build 'molecular bridges' between themselves, suppressing the immune response. An antibody treatment that blocks these bridges was shown to restore the immune system's ability to attack with force, inhibiting tumor growth in a mouse model.
Researchers developed biodegradable polymeric nanoparticles that selectively target cancer cells with two approved drug pairs for skin and breast cancers. The treatment showed significantly enhanced therapeutic effects, reduced tumor size, and prolonged median survival in mice.
A recent study found that nearly two-fifths of women aged 40-49 did not receive biennial mammography screening, highlighting significant gaps in early detection. To optimize breast cancer detection, ensuring equitable adherence to U.S. Preventive Services Task Force recommendations is crucial.
Researchers at UC Davis Comprehensive Cancer Center have identified a biomarker called TRIM37 associated with aggressive triple-negative breast cancer (TNBC) in Black women. This finding may help develop predictive biomarkers to improve TNBC diagnosis and prognosis, particularly for early-stage patients. TRIM37 overexpression is linked...
Researchers at City of Hope have developed a blood test to identify patients with precancerous esophageal disease, offering promise for improved early screening. Additionally, the study discovered a mechanism linking aging and cellular dysfunction in breast cancer, suggesting potential biomarkers for early detection.
A pioneering study has unlocked precision medicine for breast cancer, providing a detailed roadmap of the disease's molecular evolution. The research enables targeted therapies tailored to individual tumors' molecular fingerprints, elevating survival rates and improving patient outcomes.
A new study explores whether CBD can reduce scan-related anxiety in advanced breast cancer patients, finding it was safe but did not significantly change anxiety levels. However, participants who consumed CBD experienced lower anxiety levels after treatment.
Sylvester Comprehensive Cancer Center offers expert advice on coping with holiday loss and grief. Biological age can predict early colorectal cancer risk, while research advances may lead to a cure for multiple myeloma. Blood cancer experts share insights into new treatments.
A randomized clinical trial found that cannabidiol (CBD) significantly reduced anxiety levels 2-4 hours after ingestion in women with advanced breast cancer. CBD's anxiolytic effect suggests its potential as a treatment for scan-related anxiety.
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
A new screening method combining laser analysis with AI identifies patients with breast cancer in its earliest stage, stage 1a. This non-invasive technique reveals subtle changes in the bloodstream that occur during the initial phases of the disease, outperforming existing early detection strategies.
A multimodal machine learning model outperformed clinical and genomic models in predicting outcomes for HR-positive, HER2-negative breast cancer patients receiving CDK4/6 inhibitor combinations. The model integrated clinical and genomic factors to identify high-risk patients with a 6.5-fold difference in hazard ratio.
A study found that adding anthracyclines to taxane-based chemotherapy improved survival outcomes for HR-positive, HER2-negative breast cancer patients with high risk of recurrence. The OncotypeDX genomic test helped identify which patients could benefit from the addition.
The ZEST trial found that patients with detectable circulating tumor DNA (ctDNA) were more likely to have aggressive disease characteristics. To improve outcomes, researchers recommend starting ctDNA testing during treatment rather than waiting for completion, and targeting high-risk patients with tailored therapies.
A new study shows targeted delivery of energy-disrupting gene therapy using nanoparticles shrinks glioblastoma brain tumors and aggressive breast cancer tumors in mice. The technology, mLumiOpto, induces light-activated electrical currents inside cells to disrupt mitochondria, leading to programmed cell death and DNA damage.